UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/584,076	08/23/2006	Qing Dong	34060-US-PCT	8766	
	75074 7590 12/08/2008 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.			EXAMINER	
400 TECHNOLOGY SQUARE			MOORE, SUSANNA		
CAMBRIDGE, MA 02139			ART UNIT	PAPER NUMBER	
			1624		
			MAIL DATE	DELIVERY MODE	
			12/08/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/584,076	DONG ET AL.				
Office Action Summary	Examiner	Art Unit				
	SUSANNA MOORE	1624				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply	/ IO OFT TO EVENE - MONTH!	0) 00 THETY (00) DAY(0				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>29 Au</u>	ıgust 2008.					
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	33 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>105-123</u> is/are pending in the application.						
4a) Of the above claim(s) <u>110-123</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>105-109</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9)⊠ The specification is objected to by the Examine	r.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
See the attached detailed Office action for a list	or the certified copies not receive	a.				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ite				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>8/29/2008</u> .	5)  Notice of Informal P 6)  Other:	акенк Аррисацон				

Application/Control Number: 10/584,076 Page 2

Art Unit: 1624

## **DETAILED ACTION**

Applicant's argument, see Remarks, filed 8/20/2008, with respect to Office Action mailed 3/20/2008 have been fully considered. If the rejection is not repeated in the instant office action, the rejection/objection has been withdrawn. This is a Final Office Action. In summary, claims 105-123 are currently pending and are new claims. Claims 105-109 are compound claims and are currently under consideration. Claims 110-123 are method claims, which are currently withdrawn from consideration based on the restriction requirement and Applicant's election of Group (I), without traverse.

# Information Disclosure Statement

The information disclosure statement (IDS) submitted on 8/29/2008 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

## Claim Objections

This application contains claims 110-123, drawn to an invention nonelected without traverse. A complete reply to the Final Office Action must include cancellation of nonelected subject matter or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Page 3

Regarding claim 105, the connectivity of C(O)NH to the pyrazolopyrimidine is vague.

Claim 107 recites the limitation "4-methylpiperazin-1-yl" in the 6<sup>th</sup> specie listed. There is insufficient antecedent basis for this limitation in the claim.

Claim 107 recites the limitation "6-hydroxyphenyl" in the 10<sup>th</sup> specie listed. There is insufficient antecedent basis for this limitation in the claim.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Application/Control Number: 10/584,076 Page 4

Art Unit: 1624

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached on M-F 8:00-5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Susanna Moore/ Examiner, Art Unit 1624 /Brenda L. Coleman/ Primary Examiner, Art Unit 1624